237 related articles for article (PubMed ID: 36283609)
1. Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review.
Kuroda N; Shimizu T; Hirano D; Ishikane M; Kataoka Y
J Infect Chemother; 2023 Feb; 29(2):228-231. PubMed ID: 36283609
[TBL] [Abstract][Full Text] [Related]
2. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.
Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK
Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502
[TBL] [Abstract][Full Text] [Related]
3. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
4. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult.
Dammann F; Raja M; Camargo JF
Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
6. Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox.
Suzuki T; Saito S; Tsuzuki S; Ashida S; Takakusaki M; Yoshikawa T; Shimojima M; Ebihara H; Ohmagari N; Morioka S
BMJ Open; 2023 Aug; 13(8):e069550. PubMed ID: 37527886
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital.
Mondi A; Gagliardini R; Mazzotta V; Vita S; Carletti F; Pinnetti C; Giancola ML; Specchiarello E; Lanini S; Faraglia F; Minosse C; Paulicelli J; Mariano A; Rozera G; Fontana C; Faccendini P; Maggi F; Girardi E; Vaia F; Nicastri E; Antinori A
J Infect; 2023 Jan; 86(1):66-117. PubMed ID: 36347428
[No Abstract] [Full Text] [Related]
8. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
DeLaurentis CE; Kiser J; Zucker J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
[TBL] [Abstract][Full Text] [Related]
9. Monkeypox infection: The past, present, and future.
Upadhayay S; Arthur R; Soni D; Yadav P; Navik U; Singh R; Gurjeet Singh T; Kumar P
Int Immunopharmacol; 2022 Dec; 113(Pt A):109382. PubMed ID: 36330915
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
11. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.
Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675
[TBL] [Abstract][Full Text] [Related]
12. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Siegrist EA; Sassine J
Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
[TBL] [Abstract][Full Text] [Related]
13. Managing Monkeypox Virus: Characterizing Common Cutaneous Manifestations and Antiviral Efficacy.
Khan M; Rahman S; Ahmed F; Memon N; Haque A
J Drugs Dermatol; 2023 Mar; 22(3):282-287. PubMed ID: 36877881
[TBL] [Abstract][Full Text] [Related]
14. A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox.
Hung YP; Lee CC; Lee JC; Chiu CW; Hsueh PR; Ko WC
J Microbiol Immunol Infect; 2022 Oct; 55(5):795-802. PubMed ID: 36115792
[TBL] [Abstract][Full Text] [Related]
15. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
[TBL] [Abstract][Full Text] [Related]
16. Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies.
Rabaan AA; Abas AH; Tallei TE; Al-Zaher MA; Al-Sheef NM; Fatimawali ; Al-Nass EZ; Al-Ebrahim EA; Effendi Y; Idroes R; Alhabib MF; Al-Fheid HA; Adam AA; Bin Emran T
J Med Virol; 2023 Jan; 95(1):e28306. PubMed ID: 36372558
[TBL] [Abstract][Full Text] [Related]
17. Emerging pharmacological strategies for treating and preventing mpox.
Grosenbach DW; Russo AT; Blum ED; Hruby DE
Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Treatment against Monkeypox: A Scoping Review.
Ortiz-Saavedra B; León-Figueroa DA; Montes-Madariaga ES; Ricardo-Martínez A; Alva N; Cabanillas-Ramirez C; Barboza JJ; Siddiq A; Coaguila Cusicanqui LA; Bonilla-Aldana DK; Rodriguez-Morales AJ
Trop Med Infect Dis; 2022 Nov; 7(11):. PubMed ID: 36355910
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Prevention and Management of Monkeypox Viral Infection in Humans.
Gujjar P; Chaudhay R; Verma I; Bansal N; Gupta S; Bansal S
Curr Drug Targets; 2023; 24(13):1032-1045. PubMed ID: 37842888
[TBL] [Abstract][Full Text] [Related]
20. The 2022 human monkeypox outbreak: Clinical review and management guidance.
Aldhaeefi M; Rungkitwattanakul D; Unonu J; Franklin CJ; Lyons J; Hager K; Daftary MN
Am J Health Syst Pharm; 2023 Jan; 80(2):44-52. PubMed ID: 36259674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
